Phase II study of bleomycin, vindesine, mitomycin C and cisplatin (BEMP) in recurrent or disseminated squamous cell carcinoma of the uterine cervix

Annals of Oncology

Volumn 18, Issue 2, 2007, Pages 275-281

  van Luijk, I F ^a,i   Coens, C ^a   van der Burg, M E L ^b   Kobierska, A ^c   Namer, M ^d   Lhomme, C ^e   Zola, P ^f   Zanetta, G ^g   Vermorken, Jan B ^h  

^a EORTC DATA CENTER   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d CENTRE ANTOINE LACASSAGNE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF TURIN   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

BEMP; Cervical cancer; Chemotherapy; Metastatic; Recurrent

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; MITOMYCIN C; VINDESINE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED CANCER; DRUG FATALITY; DRUG FEVER; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; NAUSEA AND VOMITING; PATIENT SELECTION; PELVIC DISEASE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; RISK BENEFIT ANALYSIS; SKIN METASTASIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CARCINOMA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VINDESINE;

EID: 33847278785     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl384     Document Type: Article

References (19)

1. Cannistra SA, Nilhoff JM. Cancer of the uterine cervix. NEJM 1996; 334 (16): 1030-1038.
2. Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review. Int J Gynecol Cancer 1993; 3(3):129-142.
3. Thigpen JT, Vance R, Puneky L, Khansur T. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 1995; 22 (2 Suppl 3): 16-24.
4. Rein DT, Kurbacher CM. The role of chemotherapy in invasive cancer of the cervix uteri: Current standards and future prospects. Anticancer Drugs 2001; 12 (10): 787-795.
5. Bloss JD. Chemotherapy for advanced or recurrent carcinoma of the cervix. Curr Oncol Rep 2001; 3 (1): 33-40.
6. Omura GA, Blessing JA, Vaccarello L et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 1997; 15 (1): 165-171.
7. Vermorken JB, Zanetta G, De Oliveira CF et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study. Ann Oncol 2001, 12(7): 967-974.
8. Moore DH, Blessing JA, McQuellon RP et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2004; 22 (15): 3113-3119.
9. Long HJ III, Bundy BN, Grendys EC Jr et al. Randomized phase III trial of cisplatin (P) with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005; 23 (21): 4626-4633.
10. Morris M, Brader KR, Levenback C et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16 (3): 1094-1098.
11. Pignata S, Silvestro G, Ferrari E et al. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol 1999; 17 (3): 756-760.
12. Mutch DG, Bloss JD. Gemcitabine in cervical cancer. Gynecol Oncol 2003; 90 (2 Pt 2): S8-S15.
13. Muscato MS, Perry MC, Yarbro JW. Chemotherapy of cervical carcinoma. Semin Oncol 1982; 9 (3): 373-387.
14. Vermorken JB, Mangioni C, Pecorelli S et al. Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer 2000; 10 (5): 358-365.
15. Wagenaar HC, Pecorelli S, Mangioni C et al. Phase II study of mitomycin-C and cisplatin in disseminated squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group Study. Eur J Cancer 2001; 37: 1624-1628.
16. Vermorken JB, Landoni F, Pecorelli S et al. Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study. Int J Gynecol Cancer 1991; 1: 248-252.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972; 34: 187-220.